FR2855054B1 - Moyens pour bloquer ou retarder une mort cellulaire in vitro - Google Patents

Moyens pour bloquer ou retarder une mort cellulaire in vitro

Info

Publication number
FR2855054B1
FR2855054B1 FR0306190A FR0306190A FR2855054B1 FR 2855054 B1 FR2855054 B1 FR 2855054B1 FR 0306190 A FR0306190 A FR 0306190A FR 0306190 A FR0306190 A FR 0306190A FR 2855054 B1 FR2855054 B1 FR 2855054B1
Authority
FR
France
Prior art keywords
delaying
blocking
cell death
vitro cell
vitro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0306190A
Other languages
English (en)
Other versions
FR2855054A1 (fr
Inventor
David Chauvier
Annie Borgne
Etienne Jacotot
Alain Langonne
Herve Lecoeur
Dominique Rebouillat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Theraptosis SA
Original Assignee
Theraptosis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0306190A priority Critical patent/FR2855054B1/fr
Application filed by Theraptosis SA filed Critical Theraptosis SA
Priority to CA002526493A priority patent/CA2526493A1/fr
Priority to JP2006529955A priority patent/JP4991297B2/ja
Priority to CN2004800199132A priority patent/CN1822845B/zh
Priority to PCT/EP2004/006288 priority patent/WO2004103389A2/fr
Priority to ES04734525T priority patent/ES2417062T3/es
Priority to EP04734525A priority patent/EP1626732B1/fr
Priority to US10/557,902 priority patent/US20060241034A1/en
Publication of FR2855054A1 publication Critical patent/FR2855054A1/fr
Application granted granted Critical
Publication of FR2855054B1 publication Critical patent/FR2855054B1/fr
Priority to IL172103A priority patent/IL172103A/en
Priority to US12/417,760 priority patent/US20100113369A1/en
Priority to US13/452,257 priority patent/US20120329721A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/22—Cysteine endopeptidases (3.4.22)
    • C12Y304/22055—Caspase-2 (3.4.22.55)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
FR0306190A 2003-05-22 2003-05-22 Moyens pour bloquer ou retarder une mort cellulaire in vitro Expired - Fee Related FR2855054B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR0306190A FR2855054B1 (fr) 2003-05-22 2003-05-22 Moyens pour bloquer ou retarder une mort cellulaire in vitro
US10/557,902 US20060241034A1 (en) 2003-05-22 2004-05-24 Means for preventing and treating cellular death and their biological applications
CN2004800199132A CN1822845B (zh) 2003-05-22 2004-05-24 阻止和治疗细胞死亡的手段以及它们的生物学应用
PCT/EP2004/006288 WO2004103389A2 (fr) 2003-05-22 2004-05-24 Moyens pour prevenir et traiter la mort cellulaire et applications biologiques associees
ES04734525T ES2417062T3 (es) 2003-05-22 2004-05-24 Medios para prevenir y tratar la muerte celular y sus aplicaciones biológicas
EP04734525A EP1626732B1 (fr) 2003-05-22 2004-05-24 Moyens pour prevenir et traiter la mort cellulaire et applications biologiques associees
CA002526493A CA2526493A1 (fr) 2003-05-22 2004-05-24 Moyens pour prevenir et traiter la mort cellulaire et applications biologiques associees
JP2006529955A JP4991297B2 (ja) 2003-05-22 2004-05-24 細胞死を予防および治療するための手段およびそれらの生物学的適用
IL172103A IL172103A (en) 2003-05-22 2005-11-22 Inhibitors for preventing, blocking or silencing caspase-2 activity in cell death and compositions comprising such inhibitors
US12/417,760 US20100113369A1 (en) 2003-05-22 2009-04-03 Means for preventing and treating cellular death and their biological applications
US13/452,257 US20120329721A1 (en) 2003-05-22 2012-04-20 Means for preventing and treating cellular death and their biological applications

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0306190A FR2855054B1 (fr) 2003-05-22 2003-05-22 Moyens pour bloquer ou retarder une mort cellulaire in vitro

Publications (2)

Publication Number Publication Date
FR2855054A1 FR2855054A1 (fr) 2004-11-26
FR2855054B1 true FR2855054B1 (fr) 2005-07-08

Family

ID=33396686

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0306190A Expired - Fee Related FR2855054B1 (fr) 2003-05-22 2003-05-22 Moyens pour bloquer ou retarder une mort cellulaire in vitro

Country Status (3)

Country Link
CN (1) CN1822845B (fr)
ES (1) ES2417062T3 (fr)
FR (1) FR2855054B1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2563984T3 (es) * 2008-10-22 2016-03-17 Quark Pharmaceuticals, Inc. Métodos para el tratamiento de trastornos oculares
EP2476053A4 (fr) * 2009-09-08 2014-03-12 Nodality Inc Analyse de réseaux de cellules
CN111926012A (zh) * 2020-08-14 2020-11-13 南方医科大学珠江医院 用于沉默Caspase－2mRNA表达的siRNA分子

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235493B1 (en) * 1997-08-06 2001-05-22 The Regents Of The University Of California Amino acid substituted-cresyl violet, synthetic fluorogenic substrates for the analysis of agents in individual in vivo cells or tissue
AU2001289068A1 (en) * 2000-09-20 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 2 expression

Also Published As

Publication number Publication date
CN1822845A (zh) 2006-08-23
FR2855054A1 (fr) 2004-11-26
ES2417062T3 (es) 2013-08-05
CN1822845B (zh) 2013-07-24

Similar Documents

Publication Publication Date Title
ATE354573T1 (de) ßPYRAZOLVERBINDUNGEN, DIE SICH ALS PROTEINKINASEINHIBITOREN EIGNENß
PL382306A1 (pl) Preparaty przeciwwirusowe do stosowania miejscowego
NO20034166D0 (no) Molekyl¶rkonjugater for bruk ved keftbehandling
HK1164891A1 (en) Stable and soluble antibodies inhibiting tnf(alpha)
MA28633B1 (fr) Aryl- ou heteroarylamides substitues en position ortho
EP1791563A4 (fr) Anticorps anti-cd154
HK1079099A1 (en) Quickly soluble film preparations
NO20013745D0 (no) Ventiler for bruk i brönner
AU6098600A (en) Determining antibodies to ny-eso-1 in cancer patients
IL183958A0 (en) Cancer specific antibody and cell surface proteins
ATE255114T1 (de) Tricyclische proteinkinasehemmer
DE60100940D1 (de) Pflaster mit verpackung, die schnell geöffnet werden kann
FR2855054B1 (fr) Moyens pour bloquer ou retarder une mort cellulaire in vitro
EP1542609A4 (fr) Procedes de regulation positive de l'expression antigenique dans des tumeurs
AU7402601A (en) Protein complexes and assays for screening anti-cancer agents
SI2390267T1 (sl) Stabilna in topna protitelesa, ki inhibirajo TNF(alfa)
NO20030264L (no) Munustykke for stovsuger
AU2003282241A8 (en) Antibodies for in vitro use
FR2843790B3 (fr) Dispositif anti-decrochage pour raccords hydrauliques
ITRM20050151A1 (it) Dispositivo per mescolare sostanze reattive.
FR2876562B1 (fr) Ensemble de maintien pour bebe
FR2859187B1 (fr) Conditionnement pour preparation alimentaire
TW586539U (en) Exhaust device used in plumbing system
SE0102803L (sv) Återförslutningsbar hällpip
DK1421115T3 (da) Oplöselig T-cellereceptor

Legal Events

Date Code Title Description
TP Transmission of property
ST Notification of lapse

Effective date: 20150130